What is the main purpose of this 8-K filing?

This 8-K filing is primarily to report Amgen's financial results for the fourth quarter and the full year ended December 31, 2004, as announced in their press release on January 27, 2005. It also details the non-GAAP financial measures used by the company.

Why is Amgen using non-GAAP financial measures?

Amgen uses non-GAAP financial measures to provide investors with supplemental information that they believe offers a more comparable view of financial performance. These measures exclude certain items like acquisition-related costs, retention compensation, amortization of acquired intangibles, and litigation settlements, which are considered one-time or non-recurring. The company believes this facilitates better comparisons across different periods.

What are the main events driving the non-GAAP adjustments?

The primary drivers for the non-GAAP adjustments in this filing relate to major acquisitions, specifically Tularik Inc. (August 2004) and Immunex Corporation (July 2002). Other significant adjustments include the Genentech litigation settlement, retention plans for acquired employees, amortization of acquired intangible assets (like Enbrel®), and write-offs of in-process R&D. Prior periods also saw similar adjustments related to the Immunex acquisition and other settlements.

Should investors rely solely on the non-GAAP figures?

No, investors should not rely solely on the non-GAAP figures. Amgen explicitly states that these measures are supplementary and not a substitute for or superior to measures prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Investors should always review both GAAP and non-GAAP results, along with the provided reconciliations, to form a complete understanding.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on February 2, 2005, to report on its financial results for the three and twelve months ended December 31, 2004, based on a press release issued on January 27, 2005. A significant aspect of this filing is the Company's use of non-GAAP financial measures. These adjustments primarily relate to significant acquisitions, including Tularik Inc. (acquired August 2004) and Immunex Corporation (acquired July 2002), and also encompass legal settlements, such as the Genentech litigation. The Company believes that presenting these non-GAAP measures offers investors a more comparable view of its financial performance by excluding one-time acquisition-related costs, retention bonuses, amortization of acquired intangible assets, and charges related to in-process R&D write-offs. The filing details the specific adjustments made for the current periods and also provides context by referencing similar adjustments made in prior fiscal years (2003, 2002, and 2001) related to the Immunex acquisition and other events. Investors should note that these non-GAAP figures are supplementary and not a substitute for GAAP-reported results.

Key Highlights

1Amgen reported its financial results for the fourth quarter and full year ended December 31, 2004, via a press release dated January 27, 2005.
2The company utilized non-GAAP financial measures to provide supplemental information to investors, adjusting for significant acquisition-related costs and other non-recurring items.
3Key adjustments for the twelve months ended December 31, 2004, include those related to the Tularik and Immunex acquisitions, a Genentech settlement, and the amortization of acquired intangible assets.
4For the three months ended December 31, 2004, non-GAAP adjustments focused on incremental compensation and amortization of acquired intangible assets related to the Tularik acquisition.
5Prior periods (2003, 2002, 2001) were also presented with comparable non-GAAP adjustments, primarily related to the Immunex acquisition, to facilitate year-over-year comparisons.
6The filing emphasizes that these non-GAAP measures are intended to supplement, not replace, GAAP financial results and are used internally for budgeting and financial planning.
7The company provided reconciliations of its non-GAAP measures to GAAP results in accompanying exhibits (Exhibit 99.1 and 99.2).

AMGEN INC 8-K Report, Financial Results (Feb 2, 2005)

Summary

Key Highlights

Frequently Asked Questions